DK1643976T3 - Farmaceutisk formulering omfattende levothyroxinnatrium - Google Patents
Farmaceutisk formulering omfattende levothyroxinnatriumInfo
- Publication number
- DK1643976T3 DK1643976T3 DK04740922T DK04740922T DK1643976T3 DK 1643976 T3 DK1643976 T3 DK 1643976T3 DK 04740922 T DK04740922 T DK 04740922T DK 04740922 T DK04740922 T DK 04740922T DK 1643976 T3 DK1643976 T3 DK 1643976T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical formulation
- levothyroxine sodium
- levothyroxine
- sodium
- formulation
- Prior art date
Links
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 title 1
- 229960003918 levothyroxine sodium Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316206.2A GB0316206D0 (en) | 2003-07-10 | 2003-07-10 | Pharmaceutical formulation |
| PCT/EP2004/007667 WO2005004849A2 (en) | 2003-07-10 | 2004-07-08 | Pharmaceutical formulation comprising levothyroxine sodium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1643976T3 true DK1643976T3 (da) | 2009-04-06 |
Family
ID=27741962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04740922T DK1643976T3 (da) | 2003-07-10 | 2004-07-08 | Farmaceutisk formulering omfattende levothyroxinnatrium |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7955621B2 (no) |
| EP (1) | EP1643976B1 (no) |
| JP (2) | JP4880457B2 (no) |
| KR (1) | KR101136655B1 (no) |
| CN (1) | CN100430051C (no) |
| AR (1) | AR045719A1 (no) |
| AT (1) | ATE415949T1 (no) |
| AU (1) | AU2004255466B2 (no) |
| BR (1) | BRPI0412391B8 (no) |
| CA (1) | CA2531853C (no) |
| CO (1) | CO5700710A2 (no) |
| DE (1) | DE602004018142D1 (no) |
| DK (1) | DK1643976T3 (no) |
| ES (1) | ES2319193T3 (no) |
| GB (1) | GB0316206D0 (no) |
| HK (1) | HK1089094A1 (no) |
| IL (1) | IL172619A (no) |
| IS (1) | IS2616B (no) |
| MA (1) | MA27898A1 (no) |
| MX (1) | MXPA06000353A (no) |
| MY (1) | MY140127A (no) |
| NO (1) | NO338465B1 (no) |
| NZ (1) | NZ544174A (no) |
| PL (1) | PL1643976T3 (no) |
| PT (1) | PT1643976E (no) |
| RU (1) | RU2349345C2 (no) |
| TW (1) | TWI329026B (no) |
| WO (1) | WO2005004849A2 (no) |
| ZA (1) | ZA200510224B (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
| JP5173832B2 (ja) * | 2006-01-06 | 2013-04-03 | インターベツト・インターナシヨナル・ベー・ベー | 濃縮液体甲状腺ホルモン組成物 |
| IT1395454B1 (it) * | 2009-03-24 | 2012-09-21 | Altergon Sa | Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale |
| ITMI20112066A1 (it) * | 2011-11-14 | 2013-05-15 | Altergon Sa | Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4 |
| US9271951B2 (en) | 2012-12-21 | 2016-03-01 | Mylan Inc. | Levothyroxine formulation with acacia |
| WO2014098886A1 (en) * | 2012-12-21 | 2014-06-26 | Mylan Inc. | Levothyroxine formulation with carrageenan |
| WO2014098887A1 (en) * | 2012-12-21 | 2014-06-26 | Mylan Inc. | Levothyroxine formulation with acacia |
| EP2932963A1 (en) | 2014-04-16 | 2015-10-21 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Stable pharmaceutical dosage forms comprising Levothyroxine sodium |
| WO2017061621A1 (ja) | 2015-10-07 | 2017-04-13 | 協和発酵キリン株式会社 | アリールアルキルアミン化合物含有医薬組成物 |
| JP6168673B2 (ja) | 2015-10-07 | 2017-07-26 | 協和発酵キリン株式会社 | アリールアルキルアミン化合物含有医薬組成物 |
| WO2018069805A2 (en) | 2016-10-10 | 2018-04-19 | Ftf Pharma Private Limited | Method for preparation of liquid oral composition of l-thyroxin |
| SG11201906890TA (en) * | 2017-02-03 | 2019-08-27 | Berlin Chemie Ag | Oral thyroid therapeutic agent |
| IT201800003615A1 (it) * | 2018-03-15 | 2019-09-15 | Altergon Sa | Formulazioni altamente stabili di ormone tiroideo in capsule molli |
| CN109988076A (zh) * | 2019-05-05 | 2019-07-09 | 上海葆隆生物科技有限公司 | 一种左甲状腺素钠杂质及其制备 |
| KR20220085086A (ko) | 2020-12-14 | 2022-06-22 | 메디케어제약 주식회사 | 갑상선 기능 저하증을 동반한 대사 증후군을 치료하는 약제학적 복합제제 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225204A (en) * | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
| WO1994006309A1 (en) * | 1992-09-22 | 1994-03-31 | Fmc Corporation | Product and process of making microcrystalline cellulose |
| GB9401879D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
| DE19541128C2 (de) * | 1995-10-27 | 1997-11-27 | Henning Berlin Gmbh & Co | Stabilisierte schilddrüsenhormonhaltige Arzneimittel |
| ATE271863T1 (de) * | 1995-11-14 | 2004-08-15 | Abbott Gmbh & Co Kg | Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren |
| JPH11286456A (ja) * | 1998-03-31 | 1999-10-19 | Lion Corp | 複合粉体組成物及び錠剤 |
| DE19821625C1 (de) * | 1998-05-15 | 2000-01-05 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| WO1999063969A1 (en) * | 1998-06-08 | 1999-12-16 | Groenewoud Pieter J | Stabilized thyroxine medications |
| JP2001064177A (ja) * | 1999-08-16 | 2001-03-13 | Schering Ag | ベンズアミド誘導体を有効成分とする製剤 |
| JP3435664B2 (ja) * | 1999-12-08 | 2003-08-11 | ヤンセンファーマ株式会社 | 口腔内速崩壊型錠剤及びその製造方法 |
| US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
| US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
| US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
-
2003
- 2003-07-10 GB GBGB0316206.2A patent/GB0316206D0/en not_active Ceased
-
2004
- 2004-07-08 PL PL04740922T patent/PL1643976T3/pl unknown
- 2004-07-08 MX MXPA06000353A patent/MXPA06000353A/es active IP Right Grant
- 2004-07-08 EP EP04740922A patent/EP1643976B1/en not_active Expired - Lifetime
- 2004-07-08 KR KR1020067000484A patent/KR101136655B1/ko active IP Right Grant
- 2004-07-08 TW TW093120412A patent/TWI329026B/zh active
- 2004-07-08 RU RU2006104009/15A patent/RU2349345C2/ru active
- 2004-07-08 BR BRPI0412391A patent/BRPI0412391B8/pt active IP Right Grant
- 2004-07-08 CN CNB2004800197743A patent/CN100430051C/zh not_active Expired - Lifetime
- 2004-07-08 ES ES04740922T patent/ES2319193T3/es not_active Expired - Lifetime
- 2004-07-08 WO PCT/EP2004/007667 patent/WO2005004849A2/en active IP Right Grant
- 2004-07-08 CA CA2531853A patent/CA2531853C/en not_active Expired - Lifetime
- 2004-07-08 AT AT04740922T patent/ATE415949T1/de active
- 2004-07-08 JP JP2006518170A patent/JP4880457B2/ja not_active Expired - Lifetime
- 2004-07-08 MY MYPI20042725A patent/MY140127A/en unknown
- 2004-07-08 DK DK04740922T patent/DK1643976T3/da active
- 2004-07-08 NZ NZ544174A patent/NZ544174A/en unknown
- 2004-07-08 DE DE602004018142T patent/DE602004018142D1/de not_active Expired - Lifetime
- 2004-07-08 US US10/564,148 patent/US7955621B2/en active Active
- 2004-07-08 AR ARP040102405A patent/AR045719A1/es not_active Application Discontinuation
- 2004-07-08 AU AU2004255466A patent/AU2004255466B2/en not_active Expired
- 2004-07-08 PT PT04740922T patent/PT1643976E/pt unknown
-
2005
- 2005-12-15 IL IL172619A patent/IL172619A/en active IP Right Grant
- 2005-12-15 ZA ZA200510224A patent/ZA200510224B/en unknown
- 2005-12-30 CO CO05131486A patent/CO5700710A2/es not_active Application Discontinuation
-
2006
- 2006-01-06 MA MA28702A patent/MA27898A1/fr unknown
- 2006-01-13 NO NO20060208A patent/NO338465B1/no unknown
- 2006-02-07 IS IS8287A patent/IS2616B/is unknown
- 2006-08-29 HK HK06109617.8A patent/HK1089094A1/xx unknown
-
2011
- 2011-07-21 JP JP2011160067A patent/JP2011213736A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1089094A1 (en) | Pharmaceutical formulation comprising levothyroxine sodium | |
| PT1501534E (pt) | Formulacoes farmaceuticas | |
| NO20033384D0 (no) | Farmasöytisk formulering | |
| DK1660104T3 (da) | Farmaceutisk formulering indeholdende lanthanforbindelser | |
| NO20033785L (no) | Farmasöytisk formulering | |
| DK3536344T3 (da) | Superfin formoterolformulering | |
| ITTO20010008A0 (it) | Formulazione farmaceutica | |
| DK1620118T3 (da) | Reversible pegylerede lægemidler | |
| PT1467724E (pt) | Composicao farmaceutica orodispersavel de agomelatina | |
| DE602004016967D1 (de) | Flüssige pharmazeutische palonosetronformulierungen | |
| DK1587478T3 (da) | Farmaceutisk sammensætning | |
| DE60210139D1 (de) | Pharmazeutische zusammensetzungen enthaltend tegaserod | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| DK1622612T3 (da) | Farmaceutisk formulering af natriumsaltet af telmitarsan | |
| DE60319997D1 (de) | Topische emulsionsgel-zubereitung enthaltend diclofenac-natrium | |
| ATE309789T1 (de) | Darreichungsform von ibuprofen-natrium | |
| NO20043576L (no) | Pharmaceutical formulation comprising melatonin | |
| NO20041485L (no) | Farmasoytisk formulering omfattende (R)-bicalutamid | |
| NO20044164L (no) | Farmasoytiske sammensetninger | |
| DE112004001429D2 (de) | Pharmazeutischer Wirkstoff | |
| SE0200449D0 (sv) | Pharmaceutical formulation | |
| SE0201660D0 (sv) | Pharmaceutical formulation | |
| NO20041236L (no) | Farmasoytisk formulering | |
| DE602004030921D1 (de) | Pharmazeutische zusammensetzung | |
| DOP2002000508A (es) | Composición farmaceutica |